{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:20:54Z","timestamp":1788006054073,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100278","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:18:09Z","timestamp":1785233889000},"page":"100278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1708-3776","authenticated-orcid":false,"given":"Vincenzo J.","family":"Pizzuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-6330","authenticated-orcid":false,"given":"Kathryn","family":"Colborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mckenzie","family":"Schubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Althaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakhara","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-3597","authenticated-orcid":false,"given":"Jamie L.","family":"Studts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-6556","authenticated-orcid":false,"given":"Sarah J.","family":"Schmiege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-9072","authenticated-orcid":false,"given":"Paul F.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler W.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-8221","authenticated-orcid":false,"given":"Benjamin W.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-9273","authenticated-orcid":false,"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10254","key":"10.1016\/j.bneo.2026.100278_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.bneo.2026.100278_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bneo.2026.100278_bib3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.bneo.2026.100278_bib4","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100278_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100278_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009890","article-title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry","volume":"13","author":"Landsburg","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.bneo.2026.100278_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bneo.2026.100278_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2026.100278_bib9","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100278_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bneo.2026.100278_bib11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2026.100278_bib12","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2026.100278_bib13","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100278_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.14100","article-title":"Long-term survivorship care after CAR-T cell therapy","volume":"112","author":"Puckrin","year":"2024","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100278_bib15","doi-asserted-by":"crossref","first-page":"452.e1","DOI":"10.1016\/j.jtct.2024.01.063","article-title":"Quality of life and prognostic awareness in caregivers of patients receiving chimeric antigen receptor T cell therapy","volume":"30","author":"Barata","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.bneo.2026.100278_bib16","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100278_bib17","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1182\/blood-2025-6279","article-title":"Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: results from a prospective observational study","volume":"146","author":"Efficace","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100278_bib18","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1182\/blood-2025-6278","article-title":"The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy","volume":"146","author":"Efficace","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100278_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14425","article-title":"Patient-reported outcomes in phase 3 clinical trials for blood cancers: a systematic review","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.bneo.2026.100278_bib20","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-014-2099-8","article-title":"Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bneo.2026.100278_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1402992","article-title":"Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey","volume":"14","author":"Johnson","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100278_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-024-00708-w","article-title":"Are changes in patient-reported outcomes prognostic for diffuse large B-Cell lymphoma survival? Results from the GOYA trial","volume":"8","author":"Yan","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"17","key":"10.1016\/j.bneo.2026.100278_bib23","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cam4.4692","article-title":"Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: analysis of 1239 patients from the GOYA study","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.bneo.2026.100278_bib24","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bneo.2026.100278_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clml.2024.07.018","article-title":"SOHO state of the art updates and next questions | measuring patient-reported outcomes (PROs) and treatment tolerability in patients with hematologic malignancies","volume":"25","author":"Major","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.bneo.2026.100278_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006082","article-title":"Patient-reported outcomes in adoptive cell-therapy trials: mind the gap","volume":"10","author":"Ghisoni","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2026.100278_bib27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","article-title":"Assessing quality of life and symptoms in transplantation and CAR-T recipients: expert panel recommendations from the Survivorship Special Interest Group of ASTCT","volume":"31","author":"Banerjee","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.bneo.2026.100278_bib28","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/cncr.35189","article-title":"Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients","volume":"130","author":"Shaw","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bneo.2026.100278_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2015.08.038","article-title":"PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions","volume":"73","author":"Cook","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100278_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11136-023-03559-y","article-title":"Comparison of patient-reported outcomes measurement information system (PROMIS\u00ae)-29 and PROMIS global physical and mental health scores","volume":"33","author":"Hays","year":"2024","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.bneo.2026.100278_bib31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"27","key":"10.1016\/j.bneo.2026.100278_bib32","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100278_bib33","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100278_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bneo.2026.100278_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2005.02.4786","article-title":"Prognostic biomarkers in diffuse large B-cell lymphoma","volume":"24","author":"Lossos","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2026.100278_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211013987","article-title":"Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications","volume":"12","author":"Papageorgiou","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.bneo.2026.100278_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bneo.2026.100278_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100278_bib39","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.bneo.2026.100278_bib40","doi-asserted-by":"crossref","first-page":"1219.e1","DOI":"10.1016\/j.jtct.2024.09.013","article-title":"Prospective assessment of quality of life and patient-reported toxicities over the first year after chimeric antigen receptor T-cell therapy","volume":"30","author":"Hoogland","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.bneo.2026.100278_bib41","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1182\/bloodadvances.2025017081","article-title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","volume":"9","author":"Pennings","year":"2025","journal-title":"Blood Adv"},{"issue":"34","key":"10.1016\/j.bneo.2026.100278_bib42","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.21.02163","article-title":"Pathway to precision patient-reported outcomes","volume":"39","author":"Kaufmann","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bneo.2026.100278_bib43","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1158\/1078-0432.CCR-23-0396","article-title":"Patient-reported outcomes as interradiographic predictors of response in non\u2013small cell lung cancer","volume":"29","author":"Bhatt","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bneo.2026.100278_bib44","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100278_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtct.2024.02.019","article-title":"Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.bneo.2026.100278_bib46","doi-asserted-by":"crossref","first-page":"988.e1","DOI":"10.1016\/j.jtct.2024.06.022","article-title":"Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC\/GELTAMO","volume":"30","author":"Bail\u00e9n","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.bneo.2026.100278_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009793","article-title":"CAR-T cell therapy in older adults with relapsed\/refractory LBCL: benefits and challenges","volume":"13","author":"Shune","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.bneo.2026.100278_bib48","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0959-8049(00)00447-0","article-title":"Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population","volume":"37","author":"Schwarz","year":"2001","journal-title":"Eur J Cancer"},{"issue":"30","key":"10.1016\/j.bneo.2026.100278_bib49","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100278_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:11:46Z","timestamp":1788005506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000890"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100278","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100278"}}